No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
China Resources Jiangzhong Pharmaceutical Co.,Ltd functions as a prominent Chinese manufacturer of a wide array of pharmaceutical products for the domestic market. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, such as tablets designed for stomach-strengthening and digestion promotion, lactobacillus tablets, and triple live bifidobacterium enteric-coated capsules. Other significant OTC offerings feature compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. Beyond pharmaceutical drugs, the company also provides health consumer goods. These range from general nourishing products and rehabilitation nutrition items to specialized solutions for gastrointestinal and liver health. Furthermore, China Resources Jiangzhong Pharmaceutical manufactures prescription drugs. This segment encompasses a broad selection of Traditional Chinese Medicine (TCM) products, including Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules, Zhenju Jiangya tablets, Shuangju granules, Zhikang tablets, and Shuxiong granules. It also produces chemical medications such as lumbrokinase enteric-coated capsules, Rabelagat sodium enteric-coated tablets, and chloroprocaine hydrochloride. Additionally, the company processes and supplies essential medicinal raw materials, including stir-fried Chinese jujube seeds, French pinellia, and vinegar-soaked northern bupleurum. The company, headquartered in Nanchang, China, was established in 1996. It was formerly identified as Jiang Zhong Pharmaceutical Co.,Ltd before officially adopting its current name, China Resources Jiangzhong Pharmaceutical Co.,Ltd, in January 2025.
www.jzjt.comNo one on the platform currently holds 600750.SS.
No tracked institution reports a position in 600750.SS as of their last filing.
No one on the platform has traded 600750.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 22.3% | 24.7% | 22.1% | — | — | — |
| Rev. Growth % | -5.7% | 11.4% | ||||
| Profit Margin % | 21.7% | 17.6% | 20.2% | |||
| Free Cash Flow Margin % | 16.5% | 17.7% | 19.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.2B | -1.9% | $1.50 | $1.46–$1.55 | — | 4 |
| 2027 | $4.5B | +6.9% | $1.65 | $1.56–$1.79 | — | 5 |
| 2028 | $4.9B | +8.4% | $1.80 | $1.74–$1.88 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-22 | $0.38 | $0.32 | -16.1% |
| 2026-04-24 | $0.45 | $0.45 | -1.8% |
| 2026-01-23 | $0.37 | $0.37 | +1.1% |
| 2025-10-24 | $0.26 | $0.26 | -0.8% |
| 2025-08-21 | $0.39 | $0.39 | +0.9% |
| 2025-04-25 | $0.42 | $0.45 | +7.1% |
| 2025-01-24 | $0.24 | $0.24 | +0.0% |
| 2024-10-25 | $0.23 | $0.23 | +0.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600750.SSChina Resources Jiangzhong Pharmaceutical Co.,Ltd | $22.04 | -0.09% | $14.0B | — |
| 000403.SZPacific Shuanglin Bio-pharmacy Co., Ltd. | $10.01 | +0.10% | $9.5B | — |
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. | $11.36 | -0.87% | $9.8B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.21 | +0.43% | $9.9B | — |
| 600211.SSTibet Rhodiola Pharmaceutical Holding Co. Class A |
| $35.66 |
| -1.25% |
| $11.5B |
| — |
| 600216.SSZhejiang Medicine Co., Ltd. | $12.46 | -0.24% | $12.0B | — |
| 600267.SSZhejiang Hisun Pharmaceutical Co., Ltd. | $11.38 | +0.71% | $13.4B | — |
Source: Financial Modeling Prep · peers by sector/industry